Late pulmonary complications of treating Hodgkin lymphoma: bleomycin-induced toxicity

Bibliography

• Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin’s lymphoma. Oncologist 2012;17(3):367-76
   PubMed Web of Science ®Google Scholar
• Miltényi Z, Keresztes K, Végh J, et al. What is the price of survival in Hodgkin’ s lymphoma? Hematol Oncol 2007;25(4):178-83
   PubMed Web of Science ®Google Scholar
• Miltenyi Z, Magyari F, Simon Z, Illes A. Quality of life and fatigue in Hodgkin’s lymphoma patients. Tumori 2010;96(4):594-600
   PubMed Web of Science ®Google Scholar
• Simon Z, Keresztes K, Miltenyi Z, et al. [Our experiences in treating patients with Hodgkin disease in the last decade]. Orv Hetil 2007;148(15):675-82
   PubMedGoogle Scholar
• Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: cotswolds meeting. J Clin Oncol 1989;7(11):1630-6
   PubMed Web of Science ®Google Scholar
• Campo E, Swerdlow SH, Harris NL, et al. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117(19):5019-32
   PubMed Web of Science ®Google Scholar
• Jones PW, Quirk FH, CM B. The St George’ s respiratory questionnaire. Respir Med 1991;85(Suppl B):25-31
   PubMed Web of Science ®Google Scholar
• Global initiative for chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised. 2013. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnisis-management.pdf
   Google Scholar
• Froudarakis M, Hatzimichael E, Kyriazopoulou L, et al. Revisiting bleomycin from pathophysiology to safe clinical use. Crit Rev Oncol Hematol 2013;87(1):90-100
   PubMed Web of Science ®Google Scholar
• Avivi I, Hardak E, Shaham B, et al. Low incidence of long-term respiratory impairment in Hodgkin lymphoma survivors. Ann Hematol 2012;91(2):215-21
   PubMed Web of Science ®Google Scholar
• Product Monograph, Bleomycin Sulphate for Injection, USP. Available from: http://www.hospira.ca/english/_docs/Bleomycin_Eng.pdf
   Google Scholar
• Miltenyi Z, Simon Z, Payer E, et al. Changing patterns in the clinical pathological features of hodgkin lymphoma: a report from debrecen, hungary. ISRN Hematol 2011;2011:810708
   Google Scholar
• Buchler T, Bomanji J, Lee SM. FDG-PET in bleomycin-induced pneumonitis following ABVD chemotherapy for Hodgkin’s disease-a useful tool for monitoring pulmonary toxicity and disease activity. Haematologica 2007;92(11):e120-1
   Google Scholar
• Morikawa M, Demura Y, Mizuno S, et al. FDG positron emission tomography imaging of drug-induced pneumonitis. Ann Nucl Med 2008;22(4):335-8
   PubMed Web of Science ®Google Scholar
• Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 2005;23(30):7614-20
   PubMed Web of Science ®Google Scholar
• Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, et al. Complete resolution of life-threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin’s lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol 2011;29(24):e691-3
   Google Scholar
• Ng AK, Li S, Neuberg D, et al. A prospective study of pulmonary function in Hodgkin’s lymphoma patients. Ann Oncol 2008;19(10):1754-8
   PubMed Web of Science ®Google Scholar
• Macann A, Bredenfeld H, Muller RP, et al. Radiotherapy does not influence the severe pulmonary toxicity observed with the administration of gemcitabine and bleomycin in patients with advanced-stage Hodgkin’s lymphoma treated with the BAGCOPP regimen: a report by the German Hodgkin’s Lymphoma Study Group. Int J Radiat Oncol Biol Phys 2008;70(1):161-5
   PubMed Web of Science ®Google Scholar
• Matthews JH. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. Lancet 1993;342(8877):988
   PubMed Web of Science ®Google Scholar
• Saxman SB, Nichols CR, Einhorn LH. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor. Chest 1997;111(3):657-60
   PubMed Web of Science ®Google Scholar
• Ansell SM, Connors JM, Park SI, et al. Frontline therapy with brentuximab vedotin combined with ABVD or AVD in patients with newly diagnosed advanced stage Hodgkin lymphoma. ASH Annual Meeting Abstracts 2012;120(21):798
   Google Scholar
• Borchmann P, Eichenauer DA, Plutschow A, et al. Targeted beacopp variants in patients with newly diagnosed advanced stage classical Hodgkin lymphoma: interim results of a randomized phase II study. Blood 2013;122(21):4344
   Google Scholar